Related Experiment Video
Updated: Apr 19, 2026

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
Published on: December 22, 2016
[Efficacy of methylprednisolone therapy for electrical status epilepticus during sleep in children]
Jing Chen1, Zhixian Yang1, Xiaoyan Liu1
1The first author is now in Department of Neurology, Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjing 210008, China.
Insights
Methylprednisolone effectively treated electrical status epilepticus during sleep (ESES) and seizures in children with three epilepsy syndromes. Treatment outcomes were not significantly correlated with age at seizure onset or ESES duration.
Area of Science:
- Pediatric Neurology
- Epileptology
- Clinical Pharmacology
Context:
- Electrical status epilepticus during sleep (ESES) is a severe epilepsy syndrome in children.
- Benign childhood epilepsy with centrotemporal spikes (BECT) variants, epilepsy with continuous spikes and waves during slow sleep (CSWS), and Landau-Kleffner syndrome (LKS) are associated with ESES.
- Current treatment options for ESES require further evaluation.
Purpose:
- To assess the therapeutic efficacy of methylprednisolone in pediatric patients diagnosed with ESES.
- To evaluate the impact of methylprednisolone on ESES suppression and seizure control across different epilepsy syndromes.
Summary:
- A study analyzed 82 pediatric epilepsy patients with ESES (BECT variants, CSWS, LKS) treated with methylprednisolone. The treatment involved intravenous methylprednisolone followed by oral prednisone.
- Methylprednisolone demonstrated an 83% overall effective rate for ESES suppression and seizure improvement in the studied syndromes.
- Seizures improved within the first month, though recurrence rates varied by syndrome after one year.
Impact:
- Methylprednisolone is a viable therapeutic option for managing ESES and associated seizures in pediatric epilepsy.
- The study highlights the effectiveness of corticosteroids in addressing ESES, offering a potential treatment pathway.
- Findings suggest that treatment efficacy is independent of age at seizure onset or ESES duration, simplifying treatment considerations.
Objective:
To evaluate the therapeutic effect of methylprednisolone for electrical status epilepticus during sleep (ESES) in children.
Method:
The clinical and EEG data of 82 epilepsy patients with ESES, which included benign childhood epilepsy with centro temporal spikes (BECT) variants, epilepsy with continuous spikes and waves during slow sleep (CSWS) , Landau-Kleffner syndrome (LKS) collected from department of pediatrics, Peking University First Hospital were analyzed from July 2007 to September 2012. During ESES period, all patients received methylprednisolone treatment for three courses, which included methylprednisolone intravenous infusion for three days, followed by oral prednisone for four days every time. After three courses, prednisone [1-2 mg/(kg × d)] were taken by all patients for 6 months. The ESES phenomenon and seizures were observed before and after treatment. The efficacy of corticosteroid on ESES suppression, seizure control of three epilepsy syndrome were analyzed.
Result:
Thirty-nine cases were male and 43 cases were female. The epilepsy syndromes included 49 patients diagnosed as benign childhood epilepsy with centrotemporal spike (BECT) variants, 27 patients diagnosed as epilepsy with continuous spikes and waves during slow sleep (CSWS), and 6 patients diagnosed as LKS. Age of onset ranged from 1 year and 4 months to 11 years. The age of ESES newly monitored was from 2 years to 10 years and 8 months. The total effective rate of corticosteroid was 83% (68/82) for ESES, BECT variants was 82% (40/49), CSWS was 81% (22/27), LKS was 100% (6/6). There was no statistically significant difference in effective rates between the front two (χ² = 0.09, P > 0.05). The seizures were improved in the first month after methylprednisolone treatment in 3 epilepsy syndromes. The recurrence rate of BECT variants was 47% (23/49) , CSWS was 59% (16/27) , LKS was 50% (3/6) after 1 year follow up. There was no association between disease parameters, including age at seizure onset, duration of ESES and the treatment effect of ESES examined by Kruskal-Wallis method (χ² = 3.585, 0.932, P > 0.05).
Conclusion:
Methylprednisolone was effective for improving ESES and seizures in 3 epilepsy syndromes combined with ESES. There was no significant correlation between age at seizure onset, duration of ESES and treatment effect of ESES.
More Related Videos
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Related Concept Videos
Electroconvulsive Therapy
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...